Maneesh Paul-Satyaseela is the lead co-inventor of Enmetazobactam – the first invented-in-India anti-infective to be approved by USFDA. Since 2006, as its Program Director at Orchid Pharma, Chennai he led the invention as a biologist (along with medicinal chemist Senthilkumar UP), and is continuing to drive its approval and Phase-4 studies in India (Allecra Therapeutics GmbH, after in-licensing it, conducted its clinical trials and Regulatory approval at EMA, UKMHRA, & USFDA). He is one of the first Indian non-clinician to be conferred with the Fellow of Infectious Diseases Society of America (FIDSA).
He is trained at MAHE & Kalaburagi Univ. (India), CBER-USFDA (ORISE Fellow), Johns Hopkins Medical Institutions (Peds ID), USA & at Umea Univ. Sweden (ID), and has nearly 40 publications and 5 co-inventions (patents) to his credit. He serves as a member of UKRI’s Strategic Advisory Committee on PACE (2024-2029), Revive of GARDP (since 2019, https://revive.gardp.org/maneesh-paul) and three Biotech & skills Steering committees of Govt. Karnataka (India, 2024-25); was on IDSA’s Research (2017-19, 2023-24), and AMR Committees (2019-22). In Bengaluru (India), he has led trans-disciplinary research at Acharya Institutions, post-graduate medical research in 7 clinical disciplines at St. Martha’s Hospital, and was a clinical microbiologist at KIMS.
An AMR steward, techno-commercial enabler, influencer, & an innovator with broad research expertise in mechanisms of infectious diseases, he currently provides Advisory solutions to several organizations in microbiology & anti-infectives, and promotes planetary health & antimicrobial stewardship through AMRACE (AMR Action Collaborative Engagement, www.maneeshpaul.com)